Lifelong friends Arun Ramakrishnan and Udith Vaidyanathan are on a mission to bring precision to regulated AI. Backed by a $2.7 million seed round, their startup, LogicFlo, is reimagining how intelligent agents can transform high-stakes industries like pharma and biotech.
In an industry where precision is everything, LogicFlo is redefining how artificial intelligence operates in highly regulated sectors. Co-founded by friends Arun Ramakrishnan and Udith Vaidyanathan, the Boston- and New York-based startup is built around smart, scalable solutions that understand the gravity of compliance-heavy environments like pharma, biotech, and medtech.
Fresh off a $2.7 million seed round led by Lightspeed and backed by top healthcare and enterprise AI investors, LogicFlo is set to scale its intelligent agent platform.
“LogicFlo isn’t an easy startup to explain in five minutes to someone outside the industry,” they admit with a laugh. That’s partly because the problem they’re solving is so deeply technical—and partly because the duo has been building toward this moment since the second grade.
That same long-standing camaraderie now fuels a startup culture where deep trust meets deep tech. In this conversation, the two co-founders open up about building AI for the world’s most demanding industries and why LogicFlo might take more than a coffee chat to explain
American Bazaar: What inspired you to launch LogicFlo AI, and what problem were you most passionate about solving?
Udith Vaidyanathan: A few years ago, I was leading strategic initiatives in the CEO’s office at a global life sciences company, working closely with medical affairs, regulatory, and commercial teams. That’s when I saw it up close: The people driving some of the most critical work in healthcare — PhDs, MDs, regulatory experts — were spending most of their time not on high-leverage thinking. Not on shaping scientific strategy. But on formatting documents, tracing citations, rewriting content for compliance, and orchestrating fragmented workflows across multiple disconnected systems. It wasn’t just inefficiency. It was a systemic underutilization of the industry’s most valuable talent. These weren’t minor inefficiencies; they were bottlenecks that delayed therapies from reaching patients. What I didn’t know then was that my childhood friend of 24 years, Arun, was living the mirror image of this problem from the other side. As an ML engineer inside one of the world’s largest medtech companies. He was building cutting-edge AI systems for surgical robotics, but frustrated that the same level of intelligence wasn’t being applied to the back-office workflows slowing down innovation in life sciences. We came at it from opposite directions, commercial and technical, and reached the same conclusion: The way critical work gets done in pharma, biotech, and medtech is fundamentally broken. That’s what inspired us to start LogicFlo AI.
We weren’t interested in building another generic AI chatbot or throwing automation at the problem. Instead, we set out to build something deeper: A platform of intelligent agents that understand life sciences workflows end-to-end — agents that follow SOPs, reference literature, draft documents, and adapt to compliance requirements — all while keeping the expert fully in control. Because at the end of the day, this industry doesn’t need to move fast and break things. It needs to move precisely, and without unnecessary drag. And LogicFlo exists to make that possible — by letting experts spend their time doing what only they can do: pushing science forward.
Take us through both of your background and how your prior experiences in healthcare, AI, or entrepreneurship shape the vision of LogicFlo?
Vaidyanathan: Arun and I have known each other since the second grade. We’ve been best friends for over two decades. We went to the same primary school, middle school, high school, and even did our undergrad together at IIT. For most of our lives, we’ve grown in parallel — constantly challenging each other, learning from each other, and pushing each other forward. After IIT, we took different paths. I joined BCG as a strategy consultant, working across sectors. But it was during projects in pharma and biotech that I first saw the sheer complexity of the industry. During COVID, I had the opportunity to join Abbott and lead strategic initiatives from the CEO’s office. It was there that I came to appreciate how the sheer scale, complexity, and regulatory rigor of a global life sciences company, while entirely necessary, had inadvertently created a web of inefficiencies, siloed teams, and manual execution burdens that slowed down the very progress it aimed to protect.
READ: Prateek Prasanna wins award for AI-driven medical image analysis (July 3, 2025)
Brilliant experts were spending 80 percent of their time buried in documentation, compliance processes, and formatting, instead of focusing on high-impact scientific work. I didn’t know how to solve the problem back then but I knew I had to try. That’s what led me to Harvard Business School, where I went in with one core mission: to figure out how to meaningfully transform the way scientific work gets done. While there, I also had the chance to work with Dynamo AI, a [Y Combinator]-backed startup focused on AI privacy and security, founded by a group of MIT PhDs. That experience deepened my understanding of the frontier of AI infrastructure and its potential in high-stakes environments.
Arun, meanwhile, took an equally powerful path. After undergrad, he joined Anheuser-Busch’s global Data Science and ML Center of Excellence, before going to Purdue for his Master’s. He later worked at Solinftech, an AgTech startup, and most recently, he was a leading ML engineer at Intuitive Surgical — the company behind the Da Vinci robotic systems for non-invasive surgery. At Intuitive, Arun built high-precision, low-latency vision models deployed in real surgical settings. He was working at the bleeding edge of AI for healthcare — developing models that had to be precise, accurate, real-time, and fail-safe. If anyone understands what reliability means in a life-or-death context, it’s him. Our paths eventually re-converged around a shared realization: The smartest people in life sciences are drowning in manual work. And the promise of AI — done right — could finally set them free. That’s what shaped LogicFlo. Our vision is simple but ambitious: Build life sciences-native AI agents that are smart enough to help, safe enough to trust, and specialized enough to actually get the work done — in medical, regulatory, quality, and commercial workflows. With Arun’s deep technical rigor and my operational insight from inside the industry, we’re building LogicFlo with a fundamental respect for the complexity of life sciences and a deep belief that we can redesign how work gets done from the inside out.
Being featured at the Harvard India Conference is a major milestone. How did it come about, and what did it mean for you as a founder and also for LogicFlo’s visibility in the industry?
Vaidyanathan and Arun Ramakrishnan: It was a global competition, and one of the most rigorous we’ve participated in. Hundreds of startups applied, and after an initial screen, we were shortlisted for an in-depth diligence process that included over an hour of grilling and deep dives into our product, market, differentiation, and execution strategy. When we arrived on the day of the semifinals, we realized just how high the bar was. There were YC-backed companies, startups that had closed Shark Tank deals and here we were, a relatively unheard-of company solving a deeply specific problem in life sciences. To be honest, we had doubts.
LogicFlo isn’t an easy startup to explain in five minutes to someone outside the industry. The value is real, but it’s buried under regulatory nuance, enterprise workflows, and scientific context. Pitch competitions often reward simple stories and ours is anything but. But as we made it through the semifinals into the top 4, something clicked: Even in a compressed pitch format, the magnitude of the problem resonated. People understood how much talent is being underleveraged in life sciences, and why now is the moment for AI to actually fix it. In the final round, we focused on our strategic and technical edge and the judges, who were seasoned entrepreneurs and investors, pushed us hard. Their questions were sharp, and their feedback was some of the most thoughtful we’ve received to date. Winning the competition was a huge moment for us not just for visibility, but for conviction. It validated that the problem we’re tackling is not only real and urgent, but that our approach, our depth, and our team gave us a right to win. It gave us the confidence to double down and go all in.
Read more health tech stories from The American Bazaar
From what I understand, LogicFlo AI focuses on creating AI agents specifically for life sciences. Can you walk us through a few real-world scenarios where your technology is currently making a difference?
Vaidyanathan & Ramakrishnan: Absolutely. The kinds of workflows we’re enabling span across some of the most critical and operationally burdensome functions in commercial and medical teams within life sciences organizations. Some of these are:
Medical Writing: Scientific communication teams often spend weeks manually synthesizing literature, aligning with brand strategy, and ensuring compliance across references, label language, and formatting. Intelligent agents can now generate draft materials that are fully referenced and aligned to scientific and regulatory standards, turning a multi-week process into something teams can iterate on quickly, without compromising rigor.
Medical Information: Responding to unsolicited product and clinical queries, especially in high-stakes commercial settings, requires speed, accuracy, and auditability. With agent support, companies can surface structured, scientifically validated responses faster, helping field medical and sales teams deliver timely answers that can move conversations forward.
Commercial Content Development: Whether it’s promotional materials, congress decks, or continuing medical education (CME) slide kits, these assets go through complex creation and MLR review cycles. Agents assist by generating compliant, brand-aligned first drafts and tracking required citations, label consistency, and versioning — freeing up experts to focus on the message, not the mechanics. In all of these scenarios, speed is only one dimension of value. What truly matters is the reallocation of expert time — from formatting and referencing to insight generation and strategic engagement. The result is not just faster outputs, but smarter, more empowered teams.
You raised a seed round in early 2025. How did you go about securing investor confidence, and what’s your fundraising advice for other South Asian entrepreneurs in emerging tech?
Vaidyanathan: We just announced our raise a few days ago. We’re definitely excited about having some resources to make our vision a reality. As for the fundraising process, we focused on earning conviction the hard way — not through hype, but through clear founder–market fit and a grounded understanding of the problem.
First, we started with deep customer pain. LogicFlo wasn’t built in a vacuum — it came from years of working inside life sciences companies, experiencing the bottlenecks firsthand, and speaking with dozens of medical, regulatory, and commercial leaders. That gave us the intellectual honesty to know where AI could actually help — and where it couldn’t.
READ: Data engine Frekil: Scaling AI for medical scans (May 21, 2025)
Second, we had a clear wedge: a trillion-dollar industry full of high-value knowledge work that had seen little meaningful automation, and where generic copilots simply wouldn’t cut it. We weren’t saying “AI for X” — we were saying: here’s the exact pain, here’s how it’s solved today, here’s why that’s failing, and here’s what we’re building instead.
Third, we had a team that could execute. Arun and I brought deep experience from both sides of the problem: healthcare operations and cutting-edge ML. That gave investors confidence that we not only understood the stakes — we knew how to build responsibly inside them. For South Asian entrepreneurs, one of our biggest strengths is our ability to question the status quo. We come from systems where we’ve had to navigate constraints — and that gives us an instinct to challenge defaults, reframe problems, and find leverage others miss. But here’s the real truth we’ve learned: As a founder, you have to be the world’s expert on the problem you’re solving. Capital is just rocket fuel. It doesn’t replace understanding, traction, or product-pain alignment. No amount of funding can shortcut the physics of solving a real-world problem — especially in a domain like life sciences. Fundraising isn’t a goal. It’s a milestone on the way to building something that matters.